Rockefeller Capital Management
BBNX

Rockefeller Capital Management’s Beta Bionics BBNX Stock Holding History

Rockefeller Capital Management’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.74K Buy
673
+630
+1,465% +$9.32K ﹤0.01% 4146
2025
Q4 		$1.31K Buy
+43
New +$1.15K ﹤0.01% 4406

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Rockefeller Capital Management's BBNX Position: Q1 2026 in Review

Rockefeller Capital Management increased its Beta Bionics (BBNX) stake by 1,465% in Q1 2026, buying an estimated $9.32K and bringing the position to 673 shares worth $6.74K. The position accounts for ﹤0.01% of the portfolio, ranked #4146.

Rockefeller Capital Management first reported a position in BBNX in Q4 2025 and has held it in 2 quarters since. 130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

  • Rockefeller Capital Management held 673 shares of Beta Bionics worth $6.74K as of Q1 2026.
  • Rockefeller Capital Management bought 630 Beta Bionics shares in Q1 2026, an estimated $9.32K.
  • Beta Bionics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #4146 holding.
  • Rockefeller Capital Management first reported a position in Beta Bionics in Q4 2025 and has held it in 2 quarters since.
  • 130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.